Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1994 1
1999 1
2001 1
2002 1
2004 1
2005 1
2007 2
2008 1
2011 2
2012 1
2013 4
2014 1
2016 2
2017 1
2018 4
2019 3
2020 2
2021 5
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG, Ferrarotto R. de Sousa LG, et al. Expert Rev Anticancer Ther. 2021 Dec;21(12):1321-1331. doi: 10.1080/14737140.2021.1996228. Epub 2021 Nov 2. Expert Rev Anticancer Ther. 2021. PMID: 34689660 Review.
INTRODUCTION: Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is associated with dismal prognosis and has limited therapeutic options. PD-1/PD-L1 axis blockade was initially shown to improve outcomes in …
INTRODUCTION: Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is assoc …
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R, Shi Y, Lv S, Dai T, Zhang F, Liu S, Wu B. Pei R, et al. JAMA Netw Open. 2021 May 3;4(5):e218065. doi: 10.1001/jamanetworkopen.2021.8065. JAMA Netw Open. 2021. PMID: 33956130 Free PMC article.
IMPORTANCE: Nivolumab and pembrolizumab are approved for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). ...OBJECTIVE: To evaluate the cost-effectiveness of nivolumab vs pembr …
IMPORTANCE: Nivolumab and pembrolizumab are approved for treating platinum-refractory recurrent or metastatic head and …
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
IMPORTANCE: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). OBJECTIVE: To evaluate clinical benefit of first-line nivolumab plus ipilimum …
IMPORTANCE: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell …
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma.
Bonini F, de Sousa LG, Ferrarotto R. Bonini F, et al. Expert Opin Emerg Drugs. 2023 Dec;28(2):97-106. doi: 10.1080/14728214.2023.2208345. Epub 2023 Jun 23. Expert Opin Emerg Drugs. 2023. PMID: 37144289 Review.
INTRODUCTION: Cutaneous squamous cell carcinoma (CSCC) is the second most common form of human cancer. ...A subset of patients are not candidates for curative-intent therapies due to extent of loco-regional disease, refractoriness to prior local …
INTRODUCTION: Cutaneous squamous cell carcinoma (CSCC) is the second most common form of human cancer. ...A subset of p …
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J. Zhou C, et al. Future Oncol. 2022 Jul;18(23):2495-2503. doi: 10.2217/fon-2021-1579. Epub 2022 Jun 15. Future Oncol. 2022. PMID: 35703115 Review.
This is an open-label, single-center, multi-cohort phase Ib trial, which consists of three cohorts, including cohort 1 (HER2 negative gastric or gastric esophageal junction adenocarcinoma), cohort 2 (esophageal squamous cell carcinoma and head and …
This is an open-label, single-center, multi-cohort phase Ib trial, which consists of three cohorts, including cohort 1 (HER2 negative gastri …
Afatinib in the treatment of head and neck squamous cell carcinoma.
Ferrarotto R, Gold KA. Ferrarotto R, et al. Expert Opin Investig Drugs. 2014 Jan;23(1):135-43. doi: 10.1517/13543784.2014.858696. Epub 2013 Nov 25. Expert Opin Investig Drugs. 2014. PMID: 24266694 Review.
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death in the United States. Treatment of locally advanced disease is associated with significant acute side effects and can lead to chron …
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of canc …
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A, Rothschild SI. Rothschild U, et al. Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018. Swiss Med Wkly. 2018. PMID: 29756633 Free article. Review.
Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomical subsites in the head and neck region. ...For recurrent/metastatic HNSCC palliative chemotherapy is standard of care. …
Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomica …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P, Vermorken JB. Specenier P, et al. Expert Rev Anticancer Ther. 2011 Apr;11(4):511-24. doi: 10.1586/era.11.20. Expert Rev Anticancer Ther. 2011. PMID: 21504318 Review.
The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). ...In a randomized Phase III trial in patients with locoregionally advanced squamous cell carcinoma of the …
The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF recep …
Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S, Weiss J. Sheth S, et al. Future Oncol. 2018 Jul;14(16):1547-1558. doi: 10.2217/fon-2017-0628. Epub 2018 Feb 21. Future Oncol. 2018. PMID: 29464975 Review.
Until recently, palliative options for the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been cytotoxic chemotherapy and EGFR inhibitors. ...In August 2016, the US F …
Until recently, palliative options for the treatment of platinum-refractory recurrent or metastatic head and neck …
Vitamin A derivatives in the prevention and treatment of human cancer.
Lippman SM, Meyskens FL Jr. Lippman SM, et al. J Am Coll Nutr. 1988 Aug;7(4):269-84. doi: 10.1080/07315724.1988.10720244. J Am Coll Nutr. 1988. PMID: 3062055 Free article. Review.
Therefore, clinical work has focused on the synthetic derivatives with higher therapeutic indexes. In human cancer prevention, retinoids have been most effective for skin diseases, including actinic keratosis, keratoacanthoma, epidermodysplasia verruciformis, dysplastic ne …
Therefore, clinical work has focused on the synthetic derivatives with higher therapeutic indexes. In human cancer prevention, retino …
35 results